Last reviewed · How we verify
NCT05364203: RVTOX
Interest of Immersive Virtual Reality on Stress During Botulinum Toxin Injections in Spasticity (RVTOX)
NA trial testing DEEPSEN virtual reality mask in Central Neurogical Impairment in 42 participants. Completed in 2 December 2024.
2 December 2024
Quick facts
| Lead sponsor | University Hospital, Clermont-Ferrand |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 42 |
| Start date | 10 May 2022 |
| Primary completion | 2 December 2024 |
| Estimated completion | 2 December 2024 |
| Sites | 1 location across France |
Drugs / interventions tested
- DEEPSEN virtual reality mask
Conditions studied
- Central Neurogical Impairment — all drugs for Central Neurogical Impairment →
Sponsor
University Hospital, Clermont-Ferrand
Who can join
18 and older, any sex, with Central Neurogical Impairment. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The main objective of the study is to investigate the effect of exposure to a virtual reality session during botulinum toxin injections on injection-induced stress. The secondary objectives are to study the effect of exposure to a virtual reality session during botulinum toxin injections, on the pain induced by the injection. And study the evolution of the effects of virtual reality with the repetition of the sessions.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Use of immersive virtual reality for stress reduction during botulinum toxin injection for spasticity (RVTOX): a study protocol of a randomised control trial.
Bougeard M, Hauret I, Pelletier-Visa M, Plan-Paquet A, et al · · 2023 · cited 1× · PMID 37903608 · DOI 10.1136/bmjopen-2022-066726 -
Musical intervention to reduce stress during botulinum toxin injection for spasticity: Protocol for a randomized controlled trial (MUSIBOT).
Angelvy P, Badin M, Pelletier-Visa M, Givron P, et al · · 2025 · PMID 41289288 · DOI 10.1371/journal.pone.0327259
Verify or expand the search:
- PubMed search for NCT05364203
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University Hospital, Clermont-Ferrand trials
Trials by the same sponsor.
- NCT07179276 — Veno-arterial Carbon Dioxide Partial Pressure Difference (CO2gap) for Early Resuscitation of Septic Shock · NA · recruiting
- NCT07476768 — PAINDYS_Characterizing Pain in Fibrous Dysplasia of Bone/McCune-Albright Syndrome: an Exploratory Pilot Study · NA · not yet recruiting
- NCT07439146 — Risk of Pneumonia in Intubated Patients in Emergency Situations · not yet recruiting
- NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
- NCT07330856 — Evaluation of Treatments for Dry or Productive Cough · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05364203 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Hospital, Clermont-Ferrand
- Last refreshed: 24 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05364203.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing